Infliximab and its biosimilar produced similar first‐year therapy outcomes in patients with inflammatory bowel disease
Author:
Affiliation:
1. Children's Hospital University of Helsinki and Helsinki University Hospital Helsinki Finland
2. University of Tampere and Tampere University Hospital Tampere Finland
Publisher
Wiley
Subject
General Medicine,Pediatrics, Perinatology and Child Health
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/apa.15026
Reference21 articles.
1. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
2. Management of Pediatric Ulcerative Colitis
3. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition
4. Infliximab dependency in pediatric Crohnʼs disease: Long-term follow-up of an unselected cohort
5. Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease;Frontiers in Immunology;2024-02-22
2. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease;Journal of Pediatric Gastroenterology and Nutrition;2024-02-09
3. Evaluation of selected serum biomarkers levels in response to the infliximab reference product (Remicade®) versus its biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study;F1000Research;2023-12-06
4. Factors that influence infliximab biosimilar trough levels in the pediatric inflammatory bowel disease population;Expert Review of Clinical Immunology;2023-11-18
5. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting;European Journal of Pediatrics;2023-10-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3